We are live on ! Find out more
ELVN icon

Enliven Therapeutics
ELVN

35 hedge funds and large institutions have $33.6M invested in Enliven Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

0.37% less ownership

Funds ownership: 14.59% → 14.22% (-0.37%)

8% less funds holding

Funds holding: 38 → 35 (-3)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

46% less capital invested

Capital invested by funds: $61.8M → $33.6M (-$28.2M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $33K

Holders
35
Holders Change
-3
Holders Change %
-7.89%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
12
Reduced
9
Closed
8
Calls
–
Puts
$33K
Net Calls
-$33K
Net Calls Change
+$27K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$2.64M
2
PVI
Pura Vida Investments
New York
+$641K
3
Renaissance Technologies
Renaissance Technologies
New York
+$542K
4
WP
Woodline Partners
California
+$512K
5
Morgan Stanley
Morgan Stanley
New York
+$132K

Top Sellers

Rank Fund Capital Flow
1
LPC
Lion Point Capital
New York
-$3.4M
2
NMC
NEA Management Company
Maryland
-$1.41M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$985K
4
Walleye Capital
Walleye Capital
New York
-$297K
5
Walleye Trading
Walleye Trading
New York
-$176K
Name Holding Trade Value Shares
Change 		Change in
Stake
OQS
26
Occudo Quantitative Strategies
Florida
$41K -$564 -43 -0.9%
Northern Trust
27
Northern Trust
Illinois
$34K – – –
Bank of America
28
Bank of America
North Carolina
$21K +$393 +30 +1%
Acadian Asset Management
29
Acadian Asset Management
Massachusetts
$19K +$28.2K +2,148 New
TRCT
30
Tower Research Capital (TRC)
New York
$11K +$8.97K +684 +129%
UBS Group
31
UBS Group
Switzerland
$10K +$14.7K +1,121 New
Federated Hermes
32
Federated Hermes
Pennsylvania
$6K +$3.61K +275 +66%
LPC
33
Lion Point Capital
New York
– -$3.4M -208,333 Closed
Walleye Trading
34
Walleye Trading
New York
– -$176K -10,808 Closed
HF
35
HRT Financial
New York
– -$94K -5,800 Closed
TI
36
Trexquant Investment
Connecticut
– -$80K -4,912 Closed
CSS
37
Cubist Systematic Strategies
Connecticut
– -$49K -2,996 Closed
ASN
38
Advisory Services Network
Georgia
– -$48K -2,920 Closed
JP Morgan Chase
39
JP Morgan Chase
New York
– -$33K -2,037 Closed
Simplex Trading
40
Simplex Trading
Illinois
– +$983 +75 New
1
2

ELVN Hedge Fund Activity: Q4 2021 in Review

35 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q4 2021, worth a combined $33.6M — down 46% from $61.8M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ELVN and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 12 added.

The largest buyer was Goldman Sachs, adding an estimated $2.64M. The largest seller was Lion Point Capital, exiting entirely with an estimated $3.4M sold.

  • 35 institutional investors held Enliven Therapeutics (ELVN) as of Q4 2021, down from 38 in Q3 2021.
  • Funds reported $33.6M of Enliven Therapeutics stock for Q4 2021, down 46% quarter-over-quarter.
  • 5 funds opened new Enliven Therapeutics positions in Q4 2021 and 8 closed out, a net change of -3 holders.
  • The largest Enliven Therapeutics buyer in Q4 2021 was Goldman Sachs, an estimated $2.64M added.
  • The largest Enliven Therapeutics seller in Q4 2021 was Lion Point Capital, an estimated $3.4M sold.

Based on aggregated 13F filings for Q4 2021.